Published Date: 08 Mar 2023
A groundbreaking study by the University of Bristol and the University of Essex has revealed new insights into the importance of early childhood for lung health.
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
2.
Patients face high out-of-pocket costs after incident cancer diagnosis
3.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
4.
The discovery of drug combinations may increase the life expectancy of children with brain cancer.
5.
A new device enhances liquid biopsy.
1.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
2.
The Risk Factors of Venous Thromboembolism and How to Lower Your Chances
3.
Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies
4.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
5.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
2.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation